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Intravenous ketamine for subacute
treatment of refractory chronic migraine:
a case series
Clinton Lauritsen1*† , Santiago Mazuera1†, Richard B. Lipton2 and Sait Ashina3
Abstract
Background: Refractory migraine is a challenging condition with great impact on health related quality of life.
Intravenous (IV) ketamine has been previously used to treat various refractory pain conditions. We present a series
of patients with refractory migraine treated with intravenous ketamine in the hospital setting.
Methods: Based on retrospective chart review, we identified six patients with refractory migraine admitted from
2010 through 2014 for treatment with intravenous ketamine. Ketamine was administered using a standard protocol
starting with a dose of 0.1 mg/kg/hr and increased by 0.1 mg/kg/hr every 3 to 4 h as tolerated until the target pain
score of 3/10 was achieved and maintained for at least 8 h. Visual Analogue Scale (VAS) scores at time of hospital
admission were obtained as well as average baseline VAS scores prior to ketamine infusion. A phone interview was
conducted for follow-up of migraine response in the 3 to 6 months following ketamine infusion.
Results: The study sample had a median age of 36.5 years (range 29–54) and 83% were women. Pre-treatment pain
scores ranged from 9 to 10. All patients achieved a target pain level of 3 or less for 8 h; the average ketamine infusion
rate at target was 0.34 mg/kg/hour (range 0.12–0.42 mg/kg/hr). One patient reported a transient out-of-body
hallucination following an increase in the infusion rate, which resolved after decreasing the rate. There were no other
significant side effects.
Conclusion: IV ketamine was safely administered in the hospital setting to patients with refractory chronic migraine.
Treatment was associated with short term improvement in pain severity in 6 of 6 patients with refractory chronic
migraine. Prospective placebo-controlled trials are needed to assess short term and long-term efficacy of IV ketamine in
refractory chronic migraine.
Background
Chronic migraine and refractory migraine have long
challenged clinicians. In the United States, chronic mi-
graine prevalence is nearly 1% and results in enormous
impact on headache-related disability, including higher
Migraine Disability Assessment Test (MIDAS), reduced
health-related quality of life (HRQoL), increased depres-
sion and anxiety (PHQ-4 and GAD-7 respectively), com-
pared to episodic migraine [1–6]. Chronic migraine has
also been shown to result in greater economic burden
and health care resource utilization [1, 3, 7–9]. Annually,
the total economic cost of chronic migraine is over three
time that of episodic migraine, when consider direct
medical costs and loss from decreased productivity [8].
Refractory migraine is included in ICHD-2 [10] and
ICHD-3 beta [11] but criteria for intractable headache
have only recently emerged [12]. Silberstein et al. [12]
assesses the type and number of treatments the patient
failed as well as the clinical setting and the intensity of
invention for intractable headache. Multiple treatment
options have been proposed for management of refrac-
tory migraine including intravenous dihydroergotamine
(DHE) and intravenous divalproex sodium [13, 14].
One candidate treatment for intractable migraine is
ketamine. Intravenous ketamine has been studied in
various refractory pain conditions including complex re-
gional pain [15]. Intranasal ketamine reduced the
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severity of aura in migraine with prolonged aura in a
small randomized trial [16]. The use of intravenous keta-
mine has only been reported in case series. Krusz et al.
[17] demonstrated improvement in pain scores in pa-
tients with refractory migraine as well as few side effects
associated with treatment.
Ketamine is a dissociative anesthetic that acts on glu-
tamate binding sites at the N-methyl-D-aspartate
(NMDA) receptor as well as at opioid, monoaminergic,
cholinergic, nicotinic, and muscarinic receptors [18].
There is a theory of functional and electrophysiological
dissociation between thalamo-neocortical and limbic
systems: sensory inputs may reach cortical receiving
areas, but fail to be observed in some of the association
areas with the use of ketamine [18]. Analysis of the
dose-dependent ketamine effects on pain processing
showed a decreasing activation of the secondary somato-
sensory cortex, insula, and anterior cingulate cortex,
which has been linked to the affective pain component
that underlines the potency of ketamine in modulating
affective pain processing [19]. This theoretical mechan-
ism of action of ketamine has shown to decrease central
sensitization and allodynia in pain conditions, which has
motived clinicians to use it as treatment for migraine.
Ketamine also reduces cortical spreading depression in
animal models [20]. Most common known side effects
of ketamine may include cardiovascular instability, re-
spiratory changes and psychiatric symptoms including
acute psychosis, hallucinations, anxiety but are usually
dose-dependent.
Herein, we report the effect of IV ketamine on a series
of six patients with intractable migraine treated with es-
calated doses on an inpatient basis.
Methods
We performed a retrospective chart review study. From
2010 until 2014, a total of six patients were admitted for
treatment with continuous intravenous ketamine to
Mount Sinai Beth Israel Hospital in New York. Data
were collected from charts obtained from the medical
record department and electronic medical records
(PRISM). The study was approved by the Mount Sinai
Institutional Review Board. Prior to admission, a diagno-
sis of chronic migraine without aura based on ICHD-2
criteria was made by a headache specialist (Sait Ashina).
Demographics, number of prior migraine treatments
and current use of medications such as opioids, antide-
pressants, beta blockers, antiepileptic medications and
nonsteroidal anti-inflammatory drugs (NSAIDs) were
documented, as well as onset age of migraine diagnosis.
All the patients received information regarding side ef-
fects and risks associated with the treatment and in-
formed written consent was obtained prior to infusion.
Monitoring of the treatment was done according to the
ketamine infusion procedure policy of the Department
of Pain Medicine and Palliative Care at Mount Sinai
Beth Israel (see Additional file 1 for sources used in
protocol development). Following an initial electrocar-
diogram (EKG) for all patients and a pregnancy test for
female patients, ketamine was administered using a
standard protocol starting with an initial intravenous in-
fusion of 0.1 mg/kg/hr. The infusion was increased by
0.1 mg/kg/hr every 3 to 4 h as tolerated until the goal
pain score of 3/10 was maintained for 8 h. The eight-
hour designation was made based on standard pain
assessment intervals in the institution. Thereafter, the in-
fusion was decreased by 0.2 mg/kg/hr every 3to 4 h until
the infusion rate reached 0 mg/kg/hr. The dose of keta-
mine escalated as needed until maximal response or
until undesirable side effects including psychomimetic
and dysphoric effects.
Visual Analogue scale (VAS) score was used at the
moment of admission and follow-up VAS scores at dif-
ferent ketamine infusion rates were assessed from nurs-
ing and infusion records. We defined a pain response as
a reduction in the initial VAS to a score of three or less.
Side effects were identified and reported.
We attempted to contact the patients in this retro-
spective study for telephone follow-up; however, we were
only able to reach two of the six patients. During tele-
phone interview, a questionnaire including MIDAS [21]
was administered.
Results
Characteristics of patients admitted for ketamine are
summarized in Table 1. Ages ranged from 29 to 54 (me-
dian of 36.5) and five out of six were women. VAS scores
on admission were nine or ten (see Table 1). All of the
patients were Caucasian. The median age of migraine
onset was 17 (range 8–29). The median duration of ill-
ness was 17 years (range 12–46). The mean number of
failed acute migraine treatments was 18 (range 14–26)
and failed preventive medications was 25 (range 7–29)
(See Table 2). Three patients out of the total six receiv-
ing ketamine had a prior psychiatric diagnosis (depres-
sion, panic attacks and/or borderline personality
disorders). In addition to chronic migraine, concomitant
chronic pain disorders were identified in three of six pa-
tients, two of whom also had a psychiatric diagnosis.
The six patients were on at least one of the following
medications: muscle relaxant, NSAID, opioid, antiepilep-
tic, antidepressant, benzodiazepine, triptan, beta blocker
or antiemetic (Table 2).
All of the six patients were started on IV ketamine
dose of 0.1 mg/kg/hr. All six patients achieved the target
endpoint of a pain score of less than three out of ten
sustained for at least 8 h. The intravenous ketamine
doses are presented in Table 1. We provide the current
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outpatient migraine regimens at the time of admission
as well as the number of acute and preventive migraine
treatments failed for each patient in Tables 2 and 3.
Telephone follow-up was obtained in just two patients,
neither of whom reported sustained benefits from intra-
venous ketamine infusion. One patient reported an out
of body hallucination which resolved following decrease
in the infusion rate.
Discussion
In this small cases series, all six patients with refractory
migraine met the target pain relief endpoint with keta-
mine over a mean infusion of 44 h (range 12–82). Mean
ketamine infusion rate at the time of pain relief endpoint
was 0.34 mg/kg/hour (range 0.12–0.42). Patients
achieved pain relief without substantial adverse effects.
One patient reported a brief dissociative experience,
which reversed.
Intravenous ketamine use in treating refractory de-
pression has recently been well established [22, 23].
Studies have also suggested a role for ketamine in the
treatment of intractable chronic pain including long-
term analgesic effect persisting beyond the duration of
infusion [24]. Long-term ketamine infusion (4–14 days)
has been shown to decrease pain for up to 3 months
[25]. Allodynia, a marker of chronic pain and central
sensitization of nociceptive pathways, has also been
shown decrease with intravenous ketamine infusion.
Interestingly, this effect was not achieved until 4–5 days
of continuous infusion [26].
The existing literature on IV ketamine for the treat-
ment of headache is limited. Though our case series is
modest in size, and in the absence of a contemporan-
eous placebo group, causal inferences are not possible,
we demonstrated short-term success in pain relief in in-
tractable migraine patients with one significant but
short-lived adverse event. It is biologically plausible that
ketamine could be an effective treatment for intractable
headache. Ketamine is an antagonist at NMDA recep-
tors, blocking the excitatory action of glutamate (Glu), a
neurotransmitter long implicated in the pathophysiology
of migraine [27]. Glu has been shown to be implicated
in induction of cortical spreading depression (CSD), acti-
vation of trigeminal nociceptive neurons as well as play
a role in central sensitization. Previous studies have
identified variants in the gene for GluA receptors in per-
sons with migraine [28].
To date, there has been a lack of treatments with reli-
able abortive effect on migraine aura, the phenomenon
attributed to CSD. In the rat-model, both ketamine and
the non-specific NMDA antagonist, MK-801 have been
shown to block CSD, demonstrated electrophysiologi-
cally and by fMRI [29]. In a double-blinded, randomized
parallel-group controlled study of 18 patients with
Table 1 The demographic and clinical data and intravenous (IV) ketamine infusion rates at which 6 patients achieved a VAS pain
score of 3 or less
Patient Age/sex Age at migraine
onset
Duration of
Illness
Psychiatric and Pain Comorbidities Initial
VAS
IV Ketamine Rate
VAS < 3
Time to maintain VAS of 3
or less for duration of 8 h
1 42/F 26 16 years Depression, Panic Attacks, Chronic Back
Pain
10 0.42 mg/kg/hr 36 h
2 29/F 15 14 years Panic Attacks 10 0.38 mg/kg/hr 40 h
3 31/M 19 12 years Complex Regional Pain Syndrome 9 0.41 mg/kg/hr 20 h
4 54/F 8 46 years None 9 0.12 mg/kg/hr 12 h
5 30/F 10 20 years Depression, Borderline Personality Disorder,
Chronic Neck Pain
9 0.35 mg/kg/hr 73 h
6 47/F 29 18 years Depression 9 0.34 mg/kg/hr 82 h
Table 2 Outpatient medical regimen in patients with chronic
migraine cases at time of scheduled treatment with intravenous
ketamine
Patient 1 2 3 4 5 6
Opioid 1 1 1
Non-steroidal anti-inflammatory 1 2 1
Anti-depressant 1 2 1 2
Muscle relaxant 1 1 1
Benzodiazepine 1 1
Anti-emetic 1 1 1 1
Neuroleptic 2 1
Anti-epileptic 2 1
Triptan 1
Anti-hypertensive 1 1 1
Table 3 Number of previously failed medications for each
patient
Patient 1 2 3 4 5 6
Abortive Medications Failed 19 NA 16 14 18 26
Preventive Medications Failed 25 5 17 28 23 29
OnabotulinumtoxinA Failed Yes NA Yes Yes Yes Yes
NA not available
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migraine with aura, Afridi et al. tested the effect of intra-
nasal ketamine compared to midazolam on aura. Keta-
mine was shown to reduce severity of aura but not
duration, whereas midazolam had no effect [16]. Intra-
nasal ketamine has been shown to consistently improve
aura symptoms in some patients with familial hemiplegic
migraine, although without significant reduction of
headache severity [30]. Note: Broadly blocking CSD with
long term administration is viewed as a model for prevent-
ive treatment [31]. Memantine is a voltage-dependent
noncompetitive antagonist at the glutamatergic NMDA
receptor, which inhibits the prolonged influx of calcium
associated with neuronal excitotoxicity. In order to iden-
tify an agent with preventive activity against refractory
and chronic migraine, Bigal, et al. administered daily
memantine to 28 patients in an unblinded protocol. Com-
pared to baseline, at 3 months, memantine decreased
headache frequency severe headaches and MIDAS scores
[32]. Ketamine may be a particularly beneficial treatment
option for patients that have failed memantine. Because
ketamine is the most potent competitive antagonist at the
NMDA-type glutamate receptor whereas memantine is a
weaker and noncompetitive antagonist, ketamine may
have greater impact on central sensitization [33]. Also of
interest, in patients concomitantly treated with opioids,
ketamine has been shown to increase pain relief.[34] This
may suggest a role for ketamine in the treatment of medi-
cation overuse headache.
Of the patients that completed follow up question-
naires, none reported lasting benefit from ketamine 3–
6 months post infusion. Prior publications have reported
lasting effects on chronic non-headache pain reduction
following long term infusions of more than 4 days. Of
note, none of the patients included in this case series re-
ceived ketamine infusion for more than 4 days. Thus, we
propose that future studies target ketamine infusions for
at least this duration. Once placebo controlled studies
on acute headache relief are performed, studies assessing
long-term benefits should begin. Strategies for maintain-
ing the effect of intravenous ketamine infusion should
also be studied, such as the ongoing administration of a
daily or as needed NMDA receptor antagonist. Re-
searchers have used similar strategies in prior studies,
such as with the use of mexiletine following lidocaine in-
fusion for chronic daily headache. In this fashion, agents
including dextromethorphan-quinidine, memantine, oral
or intranasal ketamine could be used to maintain the
benefit from NDMA receptor antagonism following
ketamine infusion [35, 36].
Conclusions
This study highlights the need for further research re-
garding new treatment options for patients who suffer
daily consequences of refractory migraine and have
failed many abortive and preventive medications. Our IV
ketamine infusion protocol, based on gradually dose es-
calation, relieves pain without substantial adverse effects.
However, future study of this benefit on short-term
headache relief needs to be conducted in a placebo-
controlled fashion and this publication may serve as the
basis for the design of such a trial.
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